<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974167</url>
  </required_header>
  <id_info>
    <org_study_id>2013/9/9 Ver1.0</org_study_id>
    <secondary_id>UMIN000011700</secondary_id>
    <nct_id>NCT01974167</nct_id>
  </id_info>
  <brief_title>Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol</brief_title>
  <acronym>e-GLORIA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>e-GLORIA trial Protocol Review Committee</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>e-GLORIA trial Protocol Review Committee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy
      compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis,
      using a randomized, open-label, parallel-group, comparative design.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in lumbar spine (L1-4) bone mineral density</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of vertebral fractures</measure>
    <time_frame>36 months</time_frame>
    <description>A vertebral fracture will be classified as a new fracture (i.e., change from grade 0 to grade 1, 2, or 3) or worsening of a prevalent fracture (i.e., change from grade 1 to grade 2 or 3, or change from grade 2 to grade 3) using a semi-quantitative [SQ] method according to the &quot;Vertebral Fracture Assessment Criteria, 2012 revised version.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (both traumatic and non-traumatic; All sites)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (both traumatic and non-traumatic; 3 Major sites)</measure>
    <time_frame>36 months</time_frame>
    <description>The 3 Major sites are defined as the forearm, humerus, and femur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (both traumatic and non-traumatic; 6 Major sites)</measure>
    <time_frame>36 months</time_frame>
    <description>The 6 Major sites are defined as the femur, lower leg, humerus, forearm, clavicle, and pelvis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (traumatic; All sites)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (traumatic; 3 Major sites)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (traumatic; 6 Major sites)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (non-traumatic; All sites)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (non-traumatic; 3 Major sites）</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (non-traumatic; 6 Major sites）</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vertebral fractures (new vertebral fractures)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vertebral fractures (worsening of prevalent vertebral fractures)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vertebral fractures (clinical vertebral fractures)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vertebral fracture (new or worsening of prevalent fractures) by glucocorticoid dose</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical vertebral fractures by glucocorticoid dose</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (all sites) by glucocorticoid dose</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (3 Major sites) by glucocorticoid dose</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (6 Major sites) by glucocorticoid dose</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vertebral fractures (new or worsening) by bone mineral density</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical vertebral fractures by bone mineral density</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (all sites) by bone mineral density</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (3 Major sites) by bone mineral density</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (6 Major sites) by bone mineral density</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vertebral fractures (new or worsening) by number of prevalent fractures</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical vertebral fractures by number of prevalent fractures</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (all sites) by number of prevalent fractures</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (3 Major sites) by number of prevalent fractures</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-vertebral fractures (6 Major sites) by number of prevalent fractures</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new vertebral fractures by severity</measure>
    <time_frame>36 months</time_frame>
    <description>Semiquantitative (SQ) method is used for grading of vertebral fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new clinical vertebral fractures by severity</measure>
    <time_frame>36 months</time_frame>
    <description>SQ method is used for grading of vertebral fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new non-vertebral fractures (all sites) by severity</measure>
    <time_frame>36 months</time_frame>
    <description>SQ method is used for grading of vertebral fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new non-vertebral fractures (3 Major sites) by severity</measure>
    <time_frame>36 months</time_frame>
    <description>SQ method is used for grading of vertebral fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new non-vertebral fractures (6 Major sites) by severity</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of osteoporotic fractures</measure>
    <time_frame>36 months</time_frame>
    <description>An osteoporotic fracture is defined as a fracture of the following sites: vertebral body, ribs, pelvis, humerus, clavicle, scapula, sternum, proximal femur, other portions of the femur, tibia, fibula, and forearm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of FRAX-defined major osteoporotic fractures</measure>
    <time_frame>36 months</time_frame>
    <description>The 4 Major sites are defined as clinical fractures of the spine, forearm, hip, and shoulder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lumbar spine bone mineral density</measure>
    <time_frame>6 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lumbar spine bone mineral density</measure>
    <time_frame>24 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lumbar spine bone mineral density</measure>
    <time_frame>36 months after the start of study drug administration (or at the time of withdrawal from the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proximal femur (total-hip) bone mineral density</measure>
    <time_frame>6 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proximal femur (total-hip) bone mineral density</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proximal femur (total-hip) bone mineral density</measure>
    <time_frame>24 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proximal femur (total-hip) bone mineral density</measure>
    <time_frame>36 months after the start of study drug administration (or at the time of withdrawal from the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in TRACP-5b bone metabolism marker</measure>
    <time_frame>6 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in TRACP-5b bone metabolism marker</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in PINP bone metabolism marker</measure>
    <time_frame>6 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in PINP bone metabolism marker</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of falls</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength (back muscle strength)</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength (back muscle strength)</measure>
    <time_frame>24 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength (back muscle strength)</measure>
    <time_frame>36 months after the start of study drug administration (or at the time of withdrawal from the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength (grip strength)</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength (grip strength)</measure>
    <time_frame>24 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength (grip strength)</measure>
    <time_frame>36 months after the start of study drug administration (or at the time of withdrawal from the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height</measure>
    <time_frame>12 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height</measure>
    <time_frame>24 months after the start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height</measure>
    <time_frame>36 months after the start of study drug administration (or at the time of withdrawal from the study)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Eldecalcitol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eldecalcitol 0.75 microgram once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfacalcidol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alfacalcidol 1 microgram once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eldecalcitol</intervention_name>
    <description>Eldecalcitol 0.75 microgram once daily orally</description>
    <arm_group_label>Eldecalcitol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfacalcidol</intervention_name>
    <description>Alfacalcidol 1 microgram once daily orally</description>
    <arm_group_label>Alfacalcidol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Patients who are currently taking or plan to take oral glucocorticoid medication
             for 3 months or longer and thus require treatment as per the 'Guidelines on the
             management and treatment of glucocorticoid-induced osteoporosis of the Japanese
             Society for Bone and mineral Research (2004),' and who meet at least one of the
             conditions below. No restriction is imposed on the underlying disease treated with the
             oral glucocorticoid medication.

             (i) Have any existing insufficiency fracture (ii) %YAM &lt;80 (iii) Oral glucocorticoid
             daily dose &gt;= 5 mg prednisolone equivalent

          -  (2) Aged between 20 and 85 years (both inclusive) at consent

          -  (3) Patients who are able to walk without assistance

          -  (4) Provided consent to participate in the study

        Exclusion Criteria:

          -  (1) BMD (L1-4 or T-Hip) T score &lt; -3.5

          -  (2) Have 3 or more vertebral fractures between L1 and L4.

          -  (3) Have 1 or more SQ grade 3 vertebral fractures, or 3 or more SQ grade 2 vertebral
             fractures.

          -  (4) Have received a bisphosphonate preparation for 2 weeks or longer within 6 months
             before the start of study treatment.

          -  (5) Have received a bisphosphonate preparation for 2 years or longer within 3 years
             before the start of study treatment.

          -  (6) Have received a parathyroid hormone preparation before the start of study
             treatment.

          -  (7) Have received one or more doses of an anti-RANKL (receptor activator of nuclear
             factor-kappa B ligand) antibody.

          -  (8) Have received one or more doses of an anti-sclerostin antibody or cathepsin K
             inhibitor.

          -  (9) Have received any other investigational product (including placebo) within 16
             weeks before the start of study treatment in the present study.

          -  (10) Have received any of the following drugs that can affect bone metabolism within 8
             weeks before the start of study treatment, with the exception of calcium preparations:
             (i) Bisphosphonates (ii) Active vitamin D preparations (including those for topical
             use) (iii) Selective estrogen receptor modulators (SERMs) (iv) Calcitonin preparations
             (v) Vitamin K2 preparations (vi) Ipriflavone preparations (vii) Reproductive hormone
             products (except those for vaginal use such as vaginal tablets and creams) (viii)
             Other drugs that can affect bone metabolism

          -  (11) Pregnant woman or woman who desires to become pregnant

          -  (12) Have corrected serum calcium &gt;= 10.4 mg/dL or &lt; 8.0 mg/dL at enrollment.

          -  (13) Have corrected urinary calcium &gt; 0.4 mg/dL GF at enrollment.

          -  (14) Have a past or current history of urinary calculus.

          -  (15) Have eGFR &lt; 30 mL/min/1.73 m2 at enrollment.

          -  (16) Have severe liver disease such as cirrhosis or severe heart disease such as
             severe cardiac failure.

          -  (17) Have active malignancy or received treatment for malignancy, including adjuvant
             therapy, within the past 3 years.

          -  (18) Have a history of hypersensitivity to eldecalcitol, alfacalcidol, or other
             vitamin D preparations.

          -  (19) Other persons judged by the investigator (or subinvestigator) to be inappropriate
             to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshio Matsumoto</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tokushima</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>e-GLORIA trial Office</last_name>
    <phone>+81-6229-8937</phone>
    <email>e-gloria@mebix.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nara Hospital Kinki University Faculty of Medicine</name>
      <address>
        <city>Ikoma</city>
        <state>Nara</state>
        <zip>630-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucocorticoid-induced osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

